Objectives-Prenatal diagnosis of complex congenital heart disease (CHD) during routine obstetric ultrasound (US) examinations improves postnatal outcomes, but sensitivity is low (<40%). Our objective was to improve our prenatal detection of complex CHD with implementation of a specific screening protocol.
ultrasound (US) examinations 8, 9 and a call from numerous medical organizations and clinicians 10 for a breakthrough in prenatal detection of complex CHD.
Prenatal detection of complex CHD provides critical information to families and health care teams, enabling them to develop a suitable care plan, including delivery at a specialized care facility when necessary. Prenatal diagnosis reduces the use of prostaglandins and mechanical ventilation, which often are used solely for transport to another care facility. 11, 12 An in utero diagnosis of complex CHD also assists clinicians in providing appropriate and timely care to neonates, 13, 14 resulting in lower rates of neonatal morbidity and mortality. 15, 16 In 2004, we developed a complex CHD-specific screening protocol targeting the critical forms of CHD, for which late diagnosis could potentially affect infant morbidity and mortality. 17 Focusing on rigorous application of a few essential techniques, the protocol was simple enough to be attainable by all sonographers yet effective at identifying most complex CHDs. The protocol was taught to all sonographers in the province of Manitoba, Canada, and was easily incorporated in routine provincial obstetric screening. This uniform implementation of the complex CHD screening protocol provides a unique opportunity to examine its impact on prenatal detection rates. Our objective was to test the effectiveness of the new complex CHD screening protocol.
Materials and Methods

Intervention and Setting
Our intervention consisted of changing the practice of sonographers during the performance of routine obstetric US examinations. Designed as a screening procedure, the protocol was used to identify any deviation from normal anatomy, without attempting to establish a precise diagnosis. All abnormal cases were referred for a secondary scan in a fetal assessment unit. We implemented the protocol across the entire province in October 2004: all 18 US departments and both fetal assessment units. 
Study Participants
This study used data prospectively collected by the province of Manitoba's pediatric cardiology program, which is the single referral service for all prenatal and postnatal pediatric cardiology services. Manitoba has approximately 15,000 births each year, and virtually all pregnant women receive a screening prenatal US examination at 18 to 23 weeks. Included were all cases of complex CHD in which an obstetric US examination was performed during the pregnancy at or after 18 weeks' gestation. The provincial program maintains a database containing information on all children with confirmed CHD.
For our study, we defined complex CHD as any CHD requiring medical, interventional, or surgical management within 1 year of birth. Our reference standard was confirmation by the pediatric cardiology service via fetal or postnatal echocardiography or postnatal cardiac surgery. We considered a true-positive result to be a screening US report describing a suspected cardiac abnormality with a final cardiac diagnosis confirmed by pediatric cardiology. Cases of confirmed complex CHD that were subsequently terminated or in which the fetus died in utero were included in the analysis. We included patients with other congenital abnormalities (eg, Down syndrome), but complex CHD cases with concomitant trisomy 13 or trisomy 18 were excluded because complex CHD confirmation could not be established in all cases. False-positive results were cases in which a complex CHD was suspected but subsequently found not to have complex CHD. The categories of heart disease that we targeted were the critical forms of CHD. When we first began, we asked sonographers to correctly identify normal versus abnormal fetal hearts; we focused on finding hypoplastic left heart syndrome, transposition of the great arteries, and cardiomegaly. We chose these 3 diseases by asking our pediatric cardiologist to prioritize the CHDs that were causing neonates to present in critical condition. As the sonographers' competence and confidence grew, we correctly identified other critical forms of CHD.
Main Outcomes
The primary outcomes were the sensitivity and positive predictive value in detecting complex CHD cases in utero. The specificity and negative predicative value could not be calculated because data are not recorded for true-negative results (as no follow-up is needed) and because some pregnancies are completed without having prenatal US examinations. We also compared results stratified by the setting where the complex CHD was first detected: US departments in community/rural hospitals, tertiary hospitals, and fetal assessment units.
To assess clinical significance, we compared the rates of neonates presenting in critical condition before and after the protocol was implemented. A critical presentation was defined as meeting 1 or more of the following criteria: (1) oxygen saturation of less than 75%, (2) presence of hypotension, and (3) presence of lactic acidosis.
Statistical Analyses
We calculated the sensitivity as the proportion of confirmed complex CHD cases that were identified during prenatal screening. The positive predictive value was the proportion of cases identified by screening that were subsequently confirmed as true-positive. The efficacy of the intervention (ie, sensitivity before the intervention compared to after the intervention) was assessed by a v 2 test with 1 degree of freedom. Statistical significance was determined at the P < .05 level.
Results
A total of 506 confirmed cases of complex CHD were included in the study (Table 1) . There were 84 patients with complex CHD in the preintervention period and 422 in the postintervention period. The sensitivity was significantly higher after implementation of the new screening protocol (P < .0001). This improvement was sustained over the entire course of the postintervention period, varying from 79% to 100%, as seen in Table 1 . The new screening protocol was also associated with consistently lower false-positive rates than were observed before the intervention. Table 2 shows the sensitivity rates for prenatal detection of complex CHD by US setting. Sensitivity rates improved in in all 3 settings, but the size of the effect varied by setting. After implementing the new screening protocol, we observed significant improvements in the sensitivity of prenatal complex CHD detection in US units in community hospitals (P < .0001) and tertiary hospitals (P 5 .0004). There was a slight but nonsignificant improvement in the fetal assessment units as well (P 5 .16). Additionally, in Table 3 , we show that there was a significant decrease in the presentation of neonates in critical condition from before to after implementation (24.3% to 13.1%, respectively; P 5 .0165).
We categorized our sensitivity for the various forms of complex CHD in Table 4 and included which view would be altered by CHD: either the 4-chamber view, outflow tracts, or in some cases both. The information from Table 4 was helpful in directing our continuing education efforts, in that it identified a need for additional training on outflow tract evaluation. 
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Discussion
The results of this study show that high detection rates are achievable with universal application of a rigorous screening protocol for complex CHD, without the need for advanced equipment. The implementation of our complex CHD-specific protocol during routine obstetric US examinations was associated with a significant increase in the average prenatal detection rate in Manitoba from 28% to 89%, and this improvement was sustained over a 10-year period. Although prenatal cardiologic screening technology has advanced notably over the last several decades, we achieved these results using standard 2-dimensional scanning techniques. Early attempts to identify CHD in the second-trimester fetus were done with echocardiography. 18 In 1995, Tegnander et al 19 studied the incorporation of the 4-chamber view in a large nonselected population during routine obstetric US examinations at 18 weeks' gestation. They reported an increase in the detection rate of complex CHD from 18% to 26% using this technique. In the early 2000s, technological advancements allowed the use of outflow tract views, which proved superior to the 4-chamber view in detecting complex CHD with conotruncal defects. 20 And although 3-and 4-dimensional imaging have been shown to be useful additions to conventional 2-dimensional scanning, 21 ,22 such approaches are not feasible for application in universal screening initiatives because of limitations in equipment and training. In recent years, clinicians and researchers have recognized the limitations of current screening practices for complex CHD. In 2007, Acherman et al 23 called for evaluation of universal fetal echocardiographic guidelines, arguing that standard prenatal US scanning fails to detect CHD in most fetuses. This same group of researchers subsequently undertook an educational program to improve prenatal detection during routine obstetric examinations. Their decentralized approach yielded a significant improvement in sensitivity, 24 with an increase from 36% in 2007 to 71% in 2014, similar to our findings.
However, there is still debate in the literature about whether it is necessary to recommend that every fetus undergo echocardiography, as such an approach would be costly and impractical for most jurisdictions. 25 The 2014 scientific statement by the American Heart Association on the diagnosis and treatment of fetal cardiac disease states, "It stands to reason that with uniform standards for training and performance, detection rates may improve, with fetal echocardiography being reserved for those expectant women in whom obstetric scanning suggests the possibility of an abnormality." 10 Our results, achieved with standard 2-dimensional scanning technology, support this measured and more feasible approach.
In addition to the improvement in complex CHD detection, our study demonstrated a number of other key successes. Prenatal complex CHD detection was accomplished without "over-referral," as reflected by the low number of false-positive results. In Manitoba, US units in community and tertiary hospitals function as first-line screening, and any abnormal cases are referred to fetal assessment units, where staff have more extensive training and experience to rule out most false-positive results. Our screening protocol helped ensure that only a very small number of cases were further referred to pediatric cardiology for diagnostic confirmation. In preventing the referral of a high number of cases for subspecialty assessment, our screening protocol contributed to efficient and effective use of valuable medical resources.
Another success was the large improvement seen in the detection rates for community hospitals, many of which are in rural areas. Prenatal detection of complex CHD is particularly valuable in rural settings. Advanced notice to families and the health care system allows for 0  0  3  0  100  Other  119  1  28  3  88  2  98  Total  510  25  59  30  377  49  88 AVSD indicates atrioventricular septal defect; DORV, double-outlet right ventricle; 4-CH, 4-chamber view; HLHS, hypoplastic left heart syndrome; HRHS, hypoplastic right heart syndrome; OFT, outflow tracts; PA-IVS, pulmonary atresia with intact ventricular septum; PA-VSD, pulmonary atresia with ventricular septal defect; Sens, sensitivity; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; and VSD, ventricular septal defect. 
Strengths and Limitations
Study limitations included not having access to results from autopsy investigations, which may have helped identify undiagnosed cases of complex CHD. Cases from families that moved out of the province during the study period could not be included because no followup data were available. The specificity and negative predictive value could not be assessed because true-negative results are not recorded, and some pregnancies proceed without an obstetric US examination. These limitations would likely have only a negligible impact on the study results. Study strengths were that every hospital US department and fetal assessment unit signed on to the study and implemented the new protocol for every routine obstetric US examination. Moreover, the sustainability of our approach is strongly supported by the continued positive results more than 10 years after implementation.
Conclusions
The use of a focused, rigorous complex CHD-specific protocol during routine obstetric US examinations facilitates early detection of the clear majority of fetal complex CHDs. The streamlined design of our protocol and its reliance on only standard 2-dimensional equipment and techniques allow for universal implementation at a very modest cost. The results shown in this article along with the methods described in our previous article provide the tools for replicating this approach in other jurisdictions.
